ALK and cancer: Notwithstanding that, a previous study based on in silico predictions identified miR-96 (i.e. miR-96-5p according to the last miRNA nomenclature conventions) to potentially bind to the ALK 3′-UTR and provided evidence that decreases in miR-96 could represent a mechanism underlying the aberrant expression of ALK in cancer cells [66].